Introducing Dr. Angélique Bordey as SVP of Neuroscience
In a significant move for its research initiatives, Cassava Sciences, Inc. (NASDAQ: SAVA) proudly welcomes Dr. Angélique Bordey to its team as Senior Vice President of Neuroscience. Her appointment marks a crucial step in the company’s endeavor to develop innovative treatments for central nervous system disorders.
Dr. Bordey's Expertise and Leadership in Neuroscience
Dr. Bordey arrives with a wealth of experience, bringing years of academic achievement and scientific excellence. Holding a tenured position at Yale School of Medicine, she will continue her academic contributions part-time while leading Cassava's preclinical efforts. Her academic background, especially in neuronal signaling and the intricacies of tuberous sclerosis complex (TSC), positions her uniquely to drive the company’s R&D initiatives.
Focus on TSC-Related Epilepsy
One of her primary responsibilities will include overseeing the investigation of simufilam as a potential solution for TSC-related epilepsy. This complex condition represents a challenging area in neurology, often requiring tailored and innovative treatment approaches. Dr. Bordey is excited at the prospect of advancing simufilam's evaluation, expressing hope that its unique mechanism of action could provide a breakthrough treatment for patients suffering from this debilitating epileptic syndrome.
Aligning Efforts with Community Needs
Dr. Bordey's joining comes at a pivotal time for Cassava as it seeks to reshape the treatment landscape for patients afflicted with TSC-related epilepsy. Rick Barry, the President and CEO of Cassava, expressed enthusiasm over her arrival, noting that her unique neuroscience expertise could lead to productive collaborations within the TSC community.
Research Background
Dr. Bordey's impressive scientific credentials include numerous significant publications and a robust history of securing grants. Her leadership within the neurosciences has been recognized for transformative research, particularly in understanding and addressing epileptic conditions.
About Cassava Sciences
Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on pioneering novel treatments for CNS disorders, including simufilam for TSC-related epilepsy. Cassava's innovative approach targets the filamin A protein, addressing unmet medical needs with potential for significant therapeutic impact.
For more information about Cassava and its research initiatives, visit www.CassavaSciences.com.
Frequently Asked Questions
What role will Dr. Bordey play at Cassava Sciences?
Dr. Bordey will serve as Senior Vice President of Neuroscience, leading research and development, particularly focusing on TSC-related epilepsy and simufilam.
What is simufilam?
Simufilam is an investigational oral small molecule developed by Cassava Sciences, targeting the filamin A protein, aimed at treating central nervous system disorders.
How does Dr. Bordey's background enhance Cassava's efforts?
Dr. Bordey’s extensive experience in neuroscience, especially in understanding rare diseases like TSC, positions her to effectively guide the preclinical program at Cassava.
What is Cassava Sciences' main focus?
Cassava Sciences is dedicated to developing innovative investigational treatments for central nervous system disorders, with a specific emphasis on TSC-related conditions.
Where can I find more information about Cassava Sciences?
More details about the company and its projects are available on their official website at www.CassavaSciences.com.
